Generic Medicine Services Seek FDA Approval in Mumbai
Steady: 0 in the last 7 days
Updated oct 22
The latest in this situation
How it started
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Generic medicine services are seeking final approval from the Food and Drug Administration (FDA). The initiative plans to introduce essential and life-saving drugs at reduced rates at Dr. R. N. Cooper Municipal General Hospital and Hinduhridaysamrat Shivsena Pramukh Balasaheb Thackeray Trauma Care Hospital in Mumbai.
From freepressjournal.in
Why it matters
The establishment of these generic drug outlets is designed to make high-quality healthcare more affordable for local residents. Officials noted that the availability of generic medicines could substantially lower healthcare costs for patients across the Mumbai North West parliamentary constituency.
From freepressjournal.in
Who's involved
- FDAThe regulatory body reviewing the proposals for generic drug centers
How it developed
Newest first. Tap a step to see who reported it.- FDA rated generic equivalent to brand Climara Pro.Sub-event
Generic medicine services are seeking FDA approval for launch.1 source
Keep exploring
The entities involved
-
FDA
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- Hemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.
Related events
- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.